Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Atogepant – an orally-administered CGRP antagonist – attenuates activation of meningeal nociceptors by CSD
Andrew M. Strassman, Agustín Melo-Carrillo, Timothy T. Houle, et al.
Cephalalgia (2022) Vol. 42, Iss. 9, pp. 933-943
Open Access | Times Cited: 19

Showing 19 citing articles:

Gepants for Acute and Preventive Migraine Treatment: A Narrative Review
Jamir Pitton Rissardo, Ana Letícia Fornari Caprara
Brain Sciences (2022) Vol. 12, Iss. 12, pp. 1612-1612
Open Access | Times Cited: 39
Meningeal Mechanisms and the Migraine Connection
Dan Levy, Michael A. Moskowitz
Annual Review of Neuroscience (2023) Vol. 46, Iss. 1, pp. 39-58
Open Access | Times Cited: 34
Mode and site of action of therapies targeting CGRP signaling
Alejandro Labastida‐Ramírez, Edoardo Caronna, Cédric Gollion, et al.
The Journal of Headache and Pain (2023) Vol. 24, Iss. 1
Open Access | Times Cited: 33
The preclinical discovery and development of atogepant for migraine prophylaxis
Carlo Baraldi, Dagmar Beier, Paolo Martelletti, et al.
Expert Opinion on Drug Discovery (2024) Vol. 19, Iss. 7, pp. 783-788
Open Access | Times Cited: 10
Role of neuropeptides in orofacial pain: A literature review
Jian Wang, Xiangtao Liu, Junzhuo Gou, et al.
Journal of Oral Rehabilitation (2024) Vol. 51, Iss. 5, pp. 898-908
Closed Access | Times Cited: 6
Novel insight into atogepant mechanisms of action in migraine prevention
Agustín Melo-Carrillo, Andrew M. Strassman, Ron S. Broide, et al.
Brain (2024) Vol. 147, Iss. 8, pp. 2884-2896
Open Access | Times Cited: 6
Calcitonin receptor, calcitonin gene-related peptide and amylin distribution in C1/2 dorsal root ganglia
Tayla A. Rees, Zoe Tasma, Michael L. Garelja, et al.
The Journal of Headache and Pain (2024) Vol. 25, Iss. 1
Open Access | Times Cited: 6
Calcitonin gene-related peptide causes migraine aura
Haidar Muhsen Al-Khazali, Håkan Ashina, Astrid Wiggers, et al.
The Journal of Headache and Pain (2023) Vol. 24, Iss. 1
Open Access | Times Cited: 13
Phase Ib, open‐label, fixed‐sequence, drug–drug interaction, safety, and tolerability study between atogepant and ubrogepant in participants with a history of migraine
Andrew Blumenfeld, Ramesh Boinpally, Rosa De Abreu Ferreira, et al.
Headache The Journal of Head and Face Pain (2023) Vol. 63, Iss. 3, pp. 322-332
Open Access | Times Cited: 12
Multimodal Migraine Management and the Pursuit of Migraine Freedom: A Narrative Review
Andrew Blumenfeld, Richard B. Lipton, Stephen D. Silberstein, et al.
Neurology and Therapy (2023) Vol. 12, Iss. 5, pp. 1533-1551
Open Access | Times Cited: 11
Evidence-based guidelines for the pharmacological treatment of migraine
Raffaele Ornello, Valeria Caponnetto, Fayyaz Ahmed, et al.
Cephalalgia (2025) Vol. 45, Iss. 4
Closed Access
Is there a role of calcitonin gene-related peptide in cortical spreading depression mechanisms?– argument con.
Agustín Melo-Carrillo
The Journal of Headache and Pain (2025) Vol. 26, Iss. 1
Open Access
Rimegepant as an acute treatment in a refractory migraine patient non-responder to two anti-CGRP monoclonal antibodies and triptans: Case report and pharmacological considerations
Andrea Burgalassi, Giulia Vigani, Alberto Boccalini, et al.
Cephalalgia Reports (2024) Vol. 7
Open Access | Times Cited: 2
The influence of pharmacodynamics and pharmacokinetics on the antimigraine efficacy and safety of novel anti-CGRPergic pharmacotherapies: a narrative review
Abimael González‐Hernández, Carlos M. Villalón
Expert Opinion on Drug Metabolism & Toxicology (2024)
Closed Access | Times Cited: 2
Efficacy and safety of eptinezumab as preventive treatment for episodic/chronic migraine: A systematic review and meta‐analysis
Yusak Mangara Tua Siahaan, Vinson Hartoyo, Timotius Ivan Hariyanto
Clinical and Experimental Pharmacology and Physiology (2022) Vol. 49, Iss. 11, pp. 1156-1168
Closed Access | Times Cited: 9
Meningeal brain borders and migraine headache genesis
Sarah Louise Christensen, Dan Levy
Trends in Neurosciences (2024)
Closed Access | Times Cited: 1
Real-World Evidence of the Safety and Effectiveness of Atogepant Added to OnabotulinumtoxinA for the Preventive Treatment of Chronic Migraine: A Retrospective Chart Review
Andrew Blumenfeld, László Mechtler, Lisa Cook, et al.
Pain and Therapy (2024)
Open Access
Sustained Effects of CGRP Blockade on Cortical Spreading Depolarization-Induced Alterations in Facial Heat Pain Threshold, Light Aversiveness, and Locomotive Activity in the Light Environment
Satoshi Kitagawa, Chunhua Tang, Miyuki Unekawa, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 22, pp. 13807-13807
Open Access | Times Cited: 2
Central generators of migraine and autonomic cephalalgias as targets for personalized pain management: Translational links
Rodrigo Noseda, Luis Villanueva
European Journal of Pain (2023) Vol. 27, Iss. 9, pp. 1126-1138
Closed Access
Page 1

Scroll to top